Liver biopsy in elevated liver functions tests? An old question revisited

Journal of Hepatology

Volumn 35, Issue 2, 2001, Pages 290-294

  Bianchi, Leonardo ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME;

ALCOHOL ABUSE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EDITORIAL; FATTY LIVER; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; PRIORITY JOURNAL; TOXIC HEPATITIS;

BILIARY TRACT DISEASES; BIOPSY, NEEDLE; FATTY LIVER; HEPATITIS, AUTOIMMUNE; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS;

EID: 0034876150     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00155-6     Document Type: Editorial

References (49)

1. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases
2. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients
3. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?
4. Raised γ-glutamyltransferases activity and the need for liver biopsy
5. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients
6. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients
7. Importance of liver puncture biopsy and endoscopic retrograde cholangiography in patients with chronic anicteric unexplained cholestasis. A retrospective study in 79 patients (French)
8. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities
9. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology
10. Evaluation of abnormal liver-enzyme results in asymptomatic patients
11. Histological grading and staging of chronic hepatitis
12. Cellular and molecular pathobiology, pharmacological intervention, and biochemical assessment of liver fibrosis
13. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology
14. Non-alcoholic steatohepatitis: Definition and pathology
15. Clinical features and natural history of non-alcoholic steatosis syndromes
16. Non-alcoholic fatty liver disease: A spectrum of clinical and pathological severity
17. Diagnosis and interpretation of steatosis and steatohepatitis
18. Non-alcoholic steatohepatitis. A study of 49 patients
19. The natural history of non-alcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
20. Non-alcoholic steatohepatitis: An expanded clinical entity
21. Two cases from the spectrum of non-alcoholic steatohepatitis
22. Unsuspected cirrhosis discovered during obesity operations
23. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
24. Treatment of non-alcoholic fatty liver: Present and emerging therapies
25. Role of S-adenosyl-L-Methionine in the treatment of liver diseases
26. Alcoholic liver disease: Natural course, mechanisms and therapeutic strategies
27. Desialylated transferrin as a serological marker of chronic excessive alcohol ingestion
28. Markers of chronic alcohol ingestion in patients with non-alcoholic steatohepatitis: An aid to diagnosis
29. Biochemical investigations in the management of liver disease
30. Dissecting out cryptogenic liver disease
31. Guidelines for diagnosis of therapeutic drug-induced liver injury in liver biopsies
32. Die Bedeutung bioptischer Befunde für die Diagnostik von Lebererkrankungen
33. Diagnosis of drug-induced liver disease
34. Compendium of agents reported to cause drug-induced liver disease
35. Drug-induced hepatotoxicity: Clinical presentation, pathogenesis, risk factors, diagnosis and treatment
36. Drug-induced liver injury
37. Causality assessment of adverse reactions to drugs II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge
38. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries
39. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
40. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting
41. Liver biopsy interpretation in hepatitis Part I: Presentation of critical morphologic features used in diagnosis (Glossary)
42. Drug-induced liver disease
43. Understanding non-cirrhotic portal hypertension: Menage a foie
44. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules
45. Diffuse nodular regenerative hyperplasia of the liver (DNRH). A clinicopathologic study of 24 cases
46. Intrahepatic portal hypertension
47. Acute and chronic hepatitis revisited
48. Liver biopsy interpretation in hepatitis Part II: Histopathology and classification of acute and chronic hepatitis / differential diagnosis
49. Hepatic granulomas: A morphologic approach to diagnosis